Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • September 15, 2025

Share

Objective:

To correct the name of a co-author in the previously published manuscript.

Key Findings:
  • Correction made to the author list of the original study.
Interpretation:

The correction ensures accurate attribution of authorship in the published research.

Limitations:
Conclusion:

Accurate authorship is crucial for academic integrity and proper citation.

Original Source(s)

Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • September 15, 2025

Related Content

Antibiotics May Not Help Mild COVID

A retrospective cohort study of more than 520,000 hospitalized patients found no clinically meaningful improvement in deterioration or mortality with early treatment targeting community-acquired pneumonia.

Contrasting methods to operationalize antibiotic exposure in clinical research: a real-world application on health care–associated Clostridioides difficile infection

Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection